Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?
The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »